IL2 and cancer: However, high-dose IL-2 administration has been confirmed to enhance immune responses by activating effector T cells against cancer (19, 20), while low-dose IL-2 was evidenced to mainly stimulate Treg cell survival and expansion and thereby control autoimmunity and inflammation.